# The Drugs Nobody Writes About

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-11-01

Canonical page: https://glpwatchdog.org/research/the-drugs-nobody-writes-about

> A pharmacovigilance study found muscle atrophy reported disproportionately with semaglutide and tirzepatide. The same table shows two older drugs of the same class reported significantly less often than average.

## Key points

- Semaglutide ROR 2.39 and tirzepatide 1.69, but exenatide 0.26 and liraglutide 0.27.
- All four act on the same receptor. A class effect would not look like this.
- FAERS counts reports, not cases. Notoriety bias is the textbook confound.
- This is NOT evidence that muscle loss is unreal. Imaging trials show it clearly.
- 142 reports over 20+ years, and 57% male in a female-skewed user population.

A pharmacovigilance study found muscle atrophy reported disproportionately often with semaglutide and tirzepatide.[1] The same table shows [exenatide](https://glpwatchdog.org/research/exenatide-byetta-bydureon-weight-loss) and liraglutide, older drugs acting on the same receptor, reported **significantly less** often than average. That pattern is the most informative thing in the paper, and it does not point at the drugs.

## What was measured

The researchers searched the FDA Adverse Event Reporting System (FAERS), the database anyone can submit a suspected drug side effect to. FDA now lists it as the Adverse Event Monitoring System (AEMS); this paper and most others use the old name.[2] Across reports filed from October 2003 to March 2024, they found 142 reports of muscle atrophy involving GLP-1 medicines. They then calculated reporting odds ratios: how often muscle atrophy appears in reports about these drugs compared with reports about everything else.

*Reporting odds ratios for muscle atrophy against all other drugs in FAERS. Above 1 means reported more often; below 1, less.[1]*

| Drug | Reporting odds ratio | 95% CI |
| --- | --- | --- |
| Semaglutide | **2.39** | 1.63 – 3.52 |
| Tirzepatide | **1.69** | 1.14 – 2.50 |
| Exenatide | **0.26** | 0.12 – 0.55 |
| Liraglutide | **0.27** | 0.09 – 0.83 |

## Read all four rows together

Every drug in that table is a GLP-1 receptor agonist. If activating that receptor caused muscle wasting, the effect should appear across the class. It would be strongest where the weight loss is largest, but present throughout.

Instead the two older agents come in at 0.26 and 0.27, meaning muscle atrophy is reported *roughly a quarter as often* in connection with them as with drugs generally. Both intervals sit well below 1. This is not an absence of signal; it is a signal pointing the other way.

> The two drugs with the signal are the two drugs in the headlines. The two without it are the two nobody writes about.

> **FAERS measures reporting, not incidence.** A reporting odds ratio counts how often something is written down, and what gets written down depends on what people are watching for. A drug under sustained media attention for a particular side effect generates reports of that side effect, from patients who now attribute a symptom to it and from clinicians who now think to record it. Pharmacovigilance calls this notoriety bias, and this is a textbook instance.

The authors are clear about this in their own conclusion: the findings should be read as *signal detection rather than evidence of causality*, and they call for studies using objective measures of muscle mass and function. That is the right conclusion from this method, and it is not what a headline will do with a reporting odds ratio of 2.39.

## What this is not saying

> **Muscle loss on these drugs is real, and this study is not evidence against it.** Body composition measured by imaging in randomized trials consistently shows lean mass falling alongside fat mass. That evidence exists and is much better than this. The point is that a spontaneous reporting database cannot measure the size of the problem, and that these particular numbers track publicity rather than physiology.

The trial evidence on what happens to lean tissue is in [lean mass on a drug versus dieting](https://glpwatchdog.org/research/lean-mass-drug-versus-dieting), and the distinction between losing muscle bulk and losing strength (which are not the same thing) is in [muscle volume versus muscle function](https://glpwatchdog.org/research/muscle-volume-versus-muscle-function).

Two further limits on the numbers above. One hundred and forty-two reports, spread across more than twenty years and many millions of prescriptions, is a very small base for any ratio. And 57% of the reports concerned men, in a population of GLP-1 users that skews substantially female. The study does not explain that oddity, and neither will we.

## How to read any FAERS study

- **It counts reports, not cases.** There is no denominator, so no rate can be calculated from it.
- **Attention drives the numerator.** Media coverage, litigation and label changes all increase reporting without changing what is happening in bodies.
- **Compare within the drug class.** If a mechanism-based effect were real, related drugs should show it. When they show the opposite, suspect the method.
- **Treat it as a question, not an answer.** Signal detection exists to decide what to study properly next.

## Frequently asked questions

### Does semaglutide cause muscle atrophy?

Lean mass does fall alongside fat mass on these drugs, which imaging studies in randomized trials show clearly. This particular study cannot establish that, because it counts adverse-event reports rather than measuring muscle.

### What did the reporting study find?

Muscle atrophy was reported disproportionately often with semaglutide (odds ratio 2.39) and tirzepatide (1.69), and significantly less often than average with exenatide (0.26) and liraglutide (0.27).

### Why does it matter that the older drugs showed the opposite?

Because they act on the same receptor. If GLP-1 activation caused muscle wasting, the effect should appear across the class. The two drugs with a raised signal are the two under intense media attention, and the two without it are the ones nobody writes about.

### What is a reporting odds ratio?

A comparison of how often a particular side effect appears in reports about one drug versus reports about all other drugs. It measures reporting behavior, not how often the effect actually occurs, because the database has no denominator.

### Should I worry about losing muscle on a GLP-1?

It is a legitimate concern supported by better evidence than this study: body composition measured directly in trials. What matters clinically is strength and function rather than bulk alone, which is a separate question with its own evidence.

## References

1. Kwan ATH, Lakhani M, McIntyre RS. Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study. Clinical Nutrition. 2026. PMID: 41864088. https://pubmed.ncbi.nlm.nih.gov/41864088/
2. U.S. Food and Drug Administration FDA Adverse Event Monitoring System (AEMS) [Formerly FDA Adverse Event Reporting System (FAERS)]. FDA. 2026. https://www.fda.gov/drugs/surveillance-post-drug-approval-activities/fda-adverse-event-monitoring-system-aems

---

Cite as: GLP Watchdog, Nora Bissett, "The Drugs Nobody Writes About", published 2026-08-20, updated 2026-11-01. https://glpwatchdog.org/research/the-drugs-nobody-writes-about

Canonical HTML page: https://glpwatchdog.org/research/the-drugs-nobody-writes-about

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
